Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
AMGen corporate logo, 1983 Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics. [6] [7] Amgen was backed by a small group of venture capitalists, and its early focus was on recombinant DNA technology and recombinant human insulin. [8]
In anticipation of Amgen’s upcoming 1Q results on April 27, Syed expects investor focus to “remain on sotorasib’s upcoming anticipated launch and combo data, Amgen’s BiTE portfolio and ...
Maridebart cafraglutide (also known as MariTide; [1] developmental name AMG 133) is an investigational drug developed by Amgen for the treatment of obesity.It is an agonist of the GLP-1 receptor (GLP-1R) and an antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR).
In June 2013, Amgen Inc offered to buy the shares of Onyx Pharmaceuticals for $120 per share, sending the shares up by around 30% after the news was announced. [18] Onyx announced on June 30, 2013, that it rejected the unsolicited proposal from Amgen. The Onyx board has authorized its financial adviser to contact potential suitors. [19]
For premium support please call: 800-290-4726 more ways to reach us
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!